欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (2): 219-221.

• 研究原著 • 上一篇    下一篇

厄贝沙坦长期治疗对原发性高血压患者左室肥厚及心功能的影响

林泽鹏, 张治伟, 赵有生, 秦迁, 方卫华   

  1. 深圳市孙逸仙心血管医院, 深圳518020, 广东
  • 收稿日期:2004-11-23 修回日期:2005-01-10 出版日期:2005-02-06 发布日期:2020-11-18
  • 通讯作者: 林泽鹏, 男, 硕士, 副主任医师, 主要从事心血管内科临床工作。Tel:(0) 13699870968 E-mail:Linzepeng@medmail.com.cn

Effects of irbesartan on left ventricular hypertrophy and cardiac function in patients with essential hypertension

LIN Ze-peng, ZHANG Zhu-wei, ZHAO You-sheng, QIN Qian, FANG Wei-hua   

  1. Sun Yat-sen Cardiovascular Hospital, Shenzhen 518020, Guangdong, China
  • Received:2004-11-23 Revised:2005-01-10 Online:2005-02-06 Published:2020-11-18

摘要: 目的:探讨血管紧张素II 受体拮抗剂(厄贝沙坦) 对原发性高血压患者左室肥厚及心功能的影响。方法:原发性高血压患者经超声心动图检查证实左室肥厚120 例, 随机分为2 组, 每组60 例。厄贝沙坦组口服150~300 mg°d-1厄贝沙坦, 阿替洛尔组口服25~50 mg°d-1 阿替洛尔, 疗程为8 个月。治疗前后各检查一次超声心动图及放射性核素心室显像, 分析治疗前后左室重量指数及左心功能参数变化, 并分析2 组间差异。结果:两组治疗后收缩压与舒张压明显下降(P<0.01) 。厄贝沙坦组治疗后,左室后壁与室间隔厚度显著下降(P<0.05), 左室重量及左室重量指数下降更显著(P<0.01);阿替洛尔组治疗后左室后壁与室间隔厚度无明显的变化, 而左室重量及左室重量指数下降显著(P<0.05) 。厄贝沙坦组治疗后左室高峰充盈率明显增加(P<0.05), 阿替洛尔组无明显变化, 厄贝沙坦组比阿替洛尔组左室高峰充盈率明显增高(P<0.05) 。结论:原发性高血压患者在厄贝沙坦治疗8个月后可使左室肥厚显著逆转及左心室舒张功能显著改善, 对左心室舒张功能的作用优于阿替洛尔。

关键词: 厄贝沙坦, 原发性高血压, 左室肥厚, 心功能, 血管紧张素II受体拮抗剂

Abstract: AIM: To explore the effects of angiotensin Ⅱ antagonist irbesartan on left ventricular hypertrophy (LVH) and cardiac function in patients with essential hypertension.METHODS: 120 patients with essential hypertension and LVH were randomized divided into two groups (n=60 in each):the irbesartan (150-300 mg°d-1) group and atenolol (25-50 mg°d-1) group, all the patients were treated for 8 months.The echocardiography and radionuclide ventriculography were examined before and after 8 months of treatment with irbesartan or atenolol.RESULTS: Data were analyzed and showed as followed:(1) After 8 months of treatment with irbesartan or atenolol, blood pressure was decreased from 159 101 to 142/89 mmHg (P<0.01) or from 161 103 to 145/90 mmHg (P<0.01), respectively.(2) Left ventricular mass index decreased from 165 to 128 g°m-2 (P<0.01) or from 163 to 139 g°m-2 (P<0.05), respectively.(3) LVPFR increased from 1.87 to 2.59 (P<0.05) in irbesartan group but no change was found in the atenolol group.CONCLUSION: Long-term treatment with irbesartan can result in a significant reduction of LVH and a significant amelioration of left ventricular diastolic function in patients with essential hypertension.

Key words: essential hypertension, irbesartan, LVH,cardiac function,angiotensin Ⅱ antagonist

中图分类号: